series-c-plus
Stage
1
Investors
About
ViraTherapeutics GmbH develops oncolytic virus therapies that selectively infect and kill cancer cells while stimulating anti-tumor immune responses.
Explore ViraTherapeutics GmbH's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.